呼吸兴奋剂

目的应用呼吸兴奋剂治疗慢性阻塞性肺病（COPD）所致呼吸衰竭（以下简称呼衰）是有争论的。

Objective There is dispute about the effect of central respiratory stimulant in treating COPD patients with respiratory failure .

呼吸兴奋剂加营养支持治疗肺性脑病疗效观察

The Efficacy of treating Lung-brain syndrome with respiratory stimulant plus nutritional supporting therapy

方法40例COPD急性期并Ⅱ型呼衰患者分为NASPI治疗组和呼吸兴奋剂治疗（对照）组，每组20例。

Methods : Forty type ⅱ respiratory failure cases in acute period of COPD were averagely divided into two groups randomly ;

目的观察比较慢性阻塞性肺疾病合并中度肺性脑病患者常规综合治疗基础上分别合用呼吸兴奋剂、无创BiPAP通气治疗、有创通气治疗三种治疗措施的疗效分析。

Objective To examine the effect of BiPAP noninvasive ventilation and respiratory stimulant drug and invasive mechanical ventilation on patients with moderate pulmonary cerebral disease .

呼吸兴奋剂吗啉吡咯酮的合成

Synthesis of a respiratory stimulant " morli pyrrolidinone "

呼吸兴奋剂香草酰二乙胺的合成工艺研究

Investigation and preparation of respiratory stimulant - ethamivan

芬氟拉明和苯丙胺类兴奋剂的固相微萃取呼吸兴奋剂、吗啡及安定等药物影响呼吸中枢的低氧反应

A study of hypoxic effects on respiratory neurons and the response to respiratory stimulants , morphine and diazepam in rabbits

方法在常规治疗的同时，实验组与对照组分别应用无创通气和呼吸兴奋剂治疗，观察2组患者治疗前、后、治疗间歇期动脉血气变化及康复例数。

Methods Patients in the experiment group was treated with noninvasive mechanical ventilation and those in the control group with respiratory analeptics . Improvement of gas analysis and numbers of cured patients were compared after treatment .

方法106例肺性脑病随机分成两组：对照组（54例）给予抗炎、氧疗等一般治疗及呼吸兴奋剂治疗；

Method 106 patients with lung-brain syndrome were randomly divided into two groups-the control group and the therapeutic group . 54 patients in the control group were cured with general treatment of anti-infective general treatment of oxygen therapy and respiratory stimulant etc.

结果应用无创正压机械通气技术可使患者的症状、体征、低氧血症及二氧化碳潴留在较短时间内恢复到较理想状态，与应用呼吸兴奋剂患者间差别有显著性意义（P<0.05）。

Results NIPPV could make the patients recover to a satisfactory conditions in symptom , sign , hypoxemia and carbon dioxide retention in a short period , and there was a significant difference compared with respiratory stimulant therapy ( P < 0.05 ) .

在指南发布之时，治疗新生儿呼吸暂停和呼吸窘迫综合症的呼吸兴奋剂和肺表面活性剂生产商未提供任何资料。

At the time of publication , there was no information from manufacturers for respiratory stimulants and pulmonary surfactants for the treatment of apnoea and respiratory distress syndrome in newborns .